{"id":"W1964407943","doi":"10.1007/s10549-012-2369-x","title":"A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer","year":2012,"lang":"en","type":"article","venue":"Breast Cancer Research and Treatment","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":79,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"National Center for Research Resources; GlaxoSmithKline","keywords":"Lapatinib; Pazopanib; Medicine; Clinical endpoint; Internal medicine; Cohort; Adverse effect; Breast cancer; Oncology; Cancer; Pharmacology; Randomized controlled trial; Trastuzumab; Sunitinib","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002980293,0.002024104,0.003068432,0.0006507334,0.0004736902,0.001016467,0.0009231102,0.001618854,0.004850843],"category_scores_gemma":[0.002380503,0.001010954,0.00199571,0.0005622054,0.0009933548,0.001105486,0.0005477246,0.003657503,0.0009618234],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000842868,"about_ca_system_score_gemma":0.001746202,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005942199,"about_ca_topic_score_gemma":0.001982929,"domain_scores_codex":[0.9988309,0.0007387141,0.00005482167,0.0001659836,0.00007899411,0.0001307889],"domain_scores_gemma":[0.9986162,0.0003396313,0.0003445362,0.0001110795,0.00008388348,0.000504625],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9492108,0.02103925,0.0008743967,0.0003994489,0.0008223501,0.00004951088,0.00005812943,0.0007100343,0.005290085,0.000145307,0.001088398,0.02031226],"study_design_scores_gemma":[0.9026644,0.09498002,0.0008192424,0.00001204205,0.0002097755,0.0000270886,0.000009714397,0.0003810067,0.000286854,0.0001163362,0.0004826393,0.0000109011],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9698953,0.004244644,0.001976047,0.001272698,0.0009726504,0.0167629,0.001726473,0.0001982586,0.002951139],"genre_scores_gemma":[0.9622519,0.003527656,0.00484586,0.002407247,0.0007932474,0.01988318,0.001877289,0.00005006012,0.004363682],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004850843,"threshold_uncertainty_score":0.01622766,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07212824753998884,"score_gpt":0.4215965446262711,"score_spread":0.3494682970862822,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}